

Asia Pacific Self-injections Market

Market Report | 2024-09-01 | 353 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

Asia-Pacific self-injection market is expected to reach USD 19.43 billion by 2031 from USD 8.51 billion in 2023, growing with a CAGR of 11.1% in the forecast period of 2024 to 2031.

Market Segmentation:

Asia-Pacific Self-injections Market, By Product Type (Self-Injection Devices and Self-Injection Formulation), Dosage Form (Single Dose and Multi-Dose), Route of Administration (Subcutaneous, Intra muscular, and Others), Application (Autoimmune Diseases, Pain Management, Emergency Drugs, Oncology, Hormonal Disorders, and Others), Age Group (Adult, Geriatric, and Pediatric), Gender (Male and Female), Distribution Channel (Direct Tender, Hospital Pharmacy, Online Pharmacy, and Others), Country (China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Philippines, New Zealand, Taiwan, Vietnam, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031

Overview of Asia Pacific Self-Injections Market Dynamics:

Driver

- Rising prevalence of chronic disease

Restraint

- High cost of self injectors

Opportunity

- Government initiatives to self-injections

Market Players:

The key market players operating in the Asia-Pacific self-injection market are listed below:

- Novo Nordisk A/S
- Johnson & Johnson Services, Inc.
- Biogen
- Amgen Inc.
- Sanofi
- AbbVie Inc.
- YPSOMED
- BD
- AstraZeneca

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- AptarGroup, Inc.
- Bayer AG
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd
- GSK plc
- Gerresheimer AG
- Haselmeier
- Ipsen Biopharmaceuticals, Inc.
- Lilly
- Midas Pharma GmbH
- Merck & Co., Inc.
- Novartis AG
- OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)
- Pfizer Inc.
- Philips-Medisize
- PharmaJet
- Recipharm AB
- SCHOTT PHARMA
- SHL Medical AG
- Societe Industrielle de Sonceboz SA
- Terumo Corporation
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- UCB Pharma
- West Pharmaceutical Services

Table of Contents:

1 INTRODUCTION	52
1.1 OBJECTIVES OF THE STUDY	52
1.2 MARKET DEFINITION	52
1.3 OVERVIEW OF ASIA-PACIFIC SELF-INJECTIONS MARKET	52
1.4 MARKETS COVERED	55
2 MARKET SEGMENTATION	58
2.1 MARKETS COVERED	58
2.2 GEOGRAPHICAL SCOPE	59
2.3 YEARS CONSIDERED FOR THE STUDY	60
2.4 CURRENCY AND PRICING	60
2.5 DBMR TRIPOD DATA VALIDATION MODEL	61
2.6 MULTIVARIATE MODELLING	64
2.7 THERAPEUTICS LIFELINE CURVE	64
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	65
2.9 DBMR MARKET POSITION GRID	66
2.10 VENDOR SHARE ANALYSIS	67
2.11 MARKET APPLICATION COVERAGE GRID	68

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.12 SECONDARY SOURCES	69
2.13 ASSUMPTIONS	69
3 EXECUTIVE SUMMARY	70
4 PREMIUM INSIGHT	76
4.1 PORTER'S FIVE FORCES	77
4.2 PESTEL ANALYSIS	78
4.3 CUSTOMIZATIONS	79
5 ASIA-PACIFIC SELF-INJECTIONS MARKET: REGULATIONS	84
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION	84
5.1.1 AUSTRALIA	84
5.1.2 CHINA	86
5.1.3 INDIA	88
5.2 REGULATORY SUBMISSIONS	89
5.2.1 PRE-SUBMISSION ACTIVITIES	89
5.2.2 DEVELOPMENT OF TECHNICAL DOCUMENTATION	90
5.3 CLINICAL EVALUATION	90
5.4 REGULATORY SUBMISSION PREPARATION	90
5.5 SUBMISSION TO REGULATORY AUTHORITY	90
5.6 REVIEW AND EVALUATION BY REGULATORY AUTHORITY	90
5.7 APPROVAL AND MARKET AUTHORIZATION	91
5.8 POST-MARKET SURVEILLANCE	91
5.9 RENEWAL AND COMPLIANCE	91
5.10 ASEAN MEDICAL DEVICE DIRECTIVE (AMDD)	91
5.11 ADOPTION OF ASIA-PACIFIC STANDARDS (ISO AND IEC)	92
5.12 COLLABORATION VIA APEC REGULATORY HARMONIZATION STEERING COMMITTEE	92
5.13 CLINICAL DATA HARMONIZATION	92
5.14 COMMON TECHNICAL DOCUMENT (CTD) FORMAT	92
5.15 POST-MARKET SURVEILLANCE AND REPORTING HARMONIZATION	92
5.16 MUTUAL RECOGNITION AGREEMENTS (MRAS)	92
5.17 TRAINING AND CAPACITY BUILDING INITIATIVES	93
5.18 NORTH AMERICA REGULATORY SCENARIO	93
5.19 MEDICAL DEVICE CLASSIFICATION	95
5.20 REGULATORY SUBMISSIONS	98
5.21 EUROPE REGULATORY SCENARIO	100
5.22 REGULATORY SUBMISSIONS	102
5.23 MIDDLE EAST AND AFRICA REGULATORY SCENARIO	104
5.24 SOUTH AMERICA REGULATORY SCENARIO	111
5.25 INTERNATIONAL HARMONIZATION	115
6 MARKET OVERVIEW	119
6.1 DRIVERS	121
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE	121
6.1.2 TECHNOLOGICAL ADVANCEMENT IN SELF INJECTIONS	121
6.1.3 INCREASE IN PATIENT AUTONOMY	122
6.1.4 RISE IN MOBILE HEALTH APPLICATIONS	122
6.2 RESTRAINTS	124
6.2.1 HIGH COST OF SELF INJECTORS	124
6.2.2 REGULATORY HURDLES AND NEED FOR PROPER TRAINING FOR SELF-INJECTION DEVICES	125

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.3 OPPORTUNITIES	126
6.3.1 GOVERNMENT INITIATIVES TO SELF-INJECTIONS	126
6.3.2 INCREASED RESEARCH AND DEVELOPMENT FOR SELF-INJECTION	127
6.3.3 GROWING DEMAND FOR BIOLOGICS AND PERSONALIZED MEDICINE	128
6.4 CHALLENGES	129
6.4.1 PATIENT RELUCTANCE TOWARDS NEEDLES	129
6.4.2 ENVIRONMENTAL CONCERNS WITH SELF-INJECTIONS	129
7 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY PRODUCT TYPE	131
7.1 OVERVIEW	132
7.2 SELF-INJECTION DEVICES	135
7.3 SELF-INJECTION FORMULATION	137
8 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY DOSAGE FORM	138
8.1 OVERVIEW	139
8.2 SINGLE DOSE	142
8.3 MULTI-DOSE	142
9 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION	143
9.1 OVERVIEW	144
9.2 SUBCUTANEOUS	147
9.3 INTRA MUSCULAR	147
9.4 OTHERS	148
10 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY APPLICATION	149
10.1 OVERVIEW	150
10.2 AUTOIMMUNE DISEASES	153
10.3 PAIN MANAGEMENT	154
10.4 EMERGENCY DRUGS	154
10.5 ONCOLOGY	155
10.6 HORMONAL DISORDERS	155
10.7 OTHERS	156
11 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY AGE GROUP	157
11.1 OVERVIEW	158
11.2 ADULT	161
11.3 GERIATRIC	161
11.4 PEDIATRIC	162
12 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY GENDER	163
12.1 OVERVIEW	164
12.2 MALE	167
12.3 FEMALE	167
13 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL	168
13.1 OVERVIEW	169
13.2 DIRECT TENDER	172
13.3 HOSPITAL PHARMACY	172
13.4 ONLINE PHARMACY	173
13.5 OTHERS	173
14 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY REGION	174
14.1 ASIA-PACIFIC	177
15 ASIA-PACIFIC SELF-INJECTIONS MARKET: COMPANY LANDSCAPE	252
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16	SWOT ANALYSIS	253
17	COMPANY PROFILES	254
17.1	NOVO NORDISK	254
17.1.1	COMPANY SNAPSHOT	254
17.1.2	REVENUE	255
17.1.3	COMPANY SHARE ANALYSIS	255
17.1.4	PRODUCT PORTFOLIO	256
17.1.5	RECENT DEVELOPMENT	257
17.2	JOHNSON & JOHNSON SERVICES, INC.	258
17.2.1	COMPANY SNAPSHOT	258
17.2.2	REVENUE ANALYSIS	258
17.2.3	COMPANY SHARE ANALYSIS	259
17.2.4	PRODUCT PORTFOLIO	259
17.2.5	RECENT DEVELOPMENT	259
17.3	BIOGEN	261
17.3.1	COMPANY SNAPSHOT	261
17.3.2	REVENUE ANALYSIS	261
17.3.3	PRODUCT PORTFOLIO	262
17.3.4	RECENT DEVELOPMENT	263
17.4	AMGEN INC.	264
17.4.1	COMPANY SNAPSHOT	264
17.4.2	REVENUE ANALYSIS	264
17.4.3	COMPANY SHARE ANALYSIS	265
17.4.4	PRODUCT PORTFOLIO	265
17.4.5	RECENT DEVELOPMENT	265
17.5	SANOFI	266
17.5.1	COMPANY SNAPSHOT	266
17.5.2	REVENUE ANALYSIS	266
17.5.3	COMPANY SHARE ANALYSIS	267
17.5.4	PRODUCT PORTFOLIO	267
17.5.5	RECENT DEVELOPMENT	268
17.6	ABBVIE INC.	269
17.6.1	COMPANY SNAPSHOT	269
17.6.2	REVENUE ANALYSIS	269
17.6.3	COMPANY SHARE ANALYSIS	270
17.6.4	PRODUCT PORTFOLIO	270
17.6.5	RECENT DEVELOPMENT	270
17.7	YPSOMED	271
17.7.1	COMPANY SNAPSHOT	271
17.7.2	REVENUE ANALYSIS	271
17.7.3	PRODUCT PORTFOLIO	272
17.7.4	RECENT DEVELOPMENT	272
17.8	BD	273
17.8.1	COMPANY SNAPSHOT	273
17.8.2	REVENUE ANALYSIS	273
17.8.3	PRODUCT PORTFOLIO	274
17.8.4	RECENT DEVELOPMENT	274

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.9	ASTRAZENECA	275
17.9.1	COMPANY SNAPSHOT	275
17.9.2	REVENUE ANALYSIS	275
17.9.3	PRODUCT PORTFOLIO	276
17.9.4	RECENT DEVELOPMENTS	276
17.10	APTARGROUP, INC.	277
17.10.1	COMPANY SNAPSHOT	277
17.10.2	REVENUE ANALYSIS	277
17.10.3	PRODUCT PORTFOLIO	278
17.10.4	RECENT DEVELOPMENTS	278
17.11	BAYER	279
17.11.1	COMPANY SNAPSHOT	279
17.11.2	REVENUE	279
17.11.3	PRODUCT PORTFOLIO	280
17.11.4	RECENT DEVELOPMENT	280
17.12	BAUSCH HEALTH COMPANIES INC.	281
17.12.1	COMPANY SNAPSHOT	281
17.12.2	REVENUE ANALYSIS	281
17.12.3	PRODUCT PORTFOLIO	282
17.13	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	283
17.13.1	COMPANY SNAPSHOT	283
17.13.2	REVENUE ANALYSIS	284
17.13.3	PRODUCT PORTFOLIO	284
17.13.4	RECENT DEVELOPMENTS	285
17.14	CREDENCE MEDSYSTEMS, INC.	286
17.14.1	COMPANY SNAPSHOT	286
17.14.2	PRODUCT PORTFOLIO	286
17.14.3	RECENT DEVELOPMENT	288
17.15	DALI MEDICAL DEVICES	289
17.15.1	COMPANY SNAPSHOT	289
17.15.2	PRODUCT PORTFOLIO	289
17.15.3	RECENT DEVELOPMENT	292
17.16	ENABLE INJECTIONS	293
17.16.1	COMPANY SNAPSHOT	293
17.16.2	PRODUCT PORTFOLIO	293
17.16.3	RECENT DEVELOPMENTS	294
17.17	E3D ELCAM DRUG DELIVERY DEVICES	296
17.17.1	COMPANY SNAPSHOT	296
17.17.2	PRODUCT PORTFOLIO	296
17.17.3	RECENT DEVELOPMENT	298
17.18	F. HOFFMANN-LA ROCHE LTD	299
17.18.1	COMPANY SNAPSHOT	299
17.18.2	REVENUE ANALYSIS	299
17.18.3	PRODUCT PORTFOLIO	300
17.18.4	RECENT DEVELOPMENT	300
17.19	GSK PLC	301
17.19.1	COMPANY SNAPSHOT	301

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.19.2 REVENUE ANALYSIS	301
17.19.3 PRODUCT PORTFOLIO	302
17.19.4 RECENT DEVELOPMENTS	302
17.20 GERRESHEIMER AG	303
17.20.1 COMPANY SNAPSHOT	303
17.20.2 REVENUE ANALYSIS	303
17.20.3 PRODUCT PORTFOLIO	304
17.20.4 RECENT DEVELOPMENTS	305
17.21 HASELMEIER	306
17.21.1 COMPANY SNAPSHOT	306
17.21.2 PRODUCT PORTFOLIO	306
17.21.3 RECENT DEVELOPMENT	308
17.22 IPSEN BIOPHARMACEUTICALS, INC.	309
17.22.1 COMPANY SNAPSHOT	309
17.22.2 REVENUE ANALYSIS	310
17.22.3 PRODUCT PORTFOLIO	310
17.22.4 RECENT DEVELOPMENT	310
17.23 LILLY	311
17.23.1 COMPANY SNAPSHOT	311
17.23.2 REVENUE ANALYSIS	311
17.23.3 PRODUCT PORTFOLIO	312
17.23.4 RECENT DEVELOPMENT	312
17.24 MIDAS PHARMA GMBH	313
17.24.1 COMPANY SNAPSHOT	313
17.24.2 PRODUCT PORTFOLIO	313
17.24.3 RECENT DEVELOPMENT	313
17.25 MERCK & CO., INC.,	314
17.25.1 COMPANY SNAPSHOT	314
17.25.2 REVENUE ANALYSIS	314
17.25.3 PRODUCT PORTFOLIO	315
17.25.4 RECENT DEVELOPMENT	315
17.26 NOVARTIS AG	316
17.26.1 COMPANY SNAPSHOT	316
17.26.2 REVENUE ANALYSIS	317
17.26.3 PRODUCT PORTFOLIO	317
17.26.4 RECENT DEVELOPMENTS	317
17.27 NEMERA	319
17.27.1 COMPANY SNAPSHOT	319
17.27.2 PRODUCT PORTFOLIO	319
17.27.3 RECENT DEVELOPMENT	321
17.28 OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)	322
17.28.1 COMPANY SNAPSHOT	322
17.28.2 PRODUCT PORTFOLIO	322
17.28.3 RECENT DEVELOPMENT	323
17.29 OWEN MUMFORD	324
17.29.1 COMPANY SNAPSHOT	324
17.29.2 PRODUCT PORTFOLIO	324

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.29.3 RECENT DEVELOPMENT	324
17.30 PFIZER INC.	325
17.30.1 COMPANY SNAPSHOT	325
17.30.2 REVENUE ANALYSIS	325
17.30.3 PRODUCT PORTFOLIO	326
17.30.4 RECENT DEVELOPMENT	326
17.30.5 RECENT DEVELOPMENT	326
17.31 PHILIP MEDSIZE	327
17.31.1 COMPANY SNAPSHOT	327
17.31.2 PRODUCT PORTFOLIO	327
17.31.3 RECENT DEVELOPMENTS	328
17.32 PHARMAJET.	329
17.32.1 COMPANY SNAPSHOT	329
17.32.2 PRODUCT PORTFOLIO	329
17.32.3 RECENT DEVELOPMENT	329
17.33 PENJET	330
17.33.1 COMPANY SNAPSHOT	330
17.33.2 1.1.4 PRODUCT PORTFOLIO	330
17.33.3 RECENT DEVELOPMENT	330
17.34 RECIPHARM AB	331
17.34.1 COMPANY SNAPSHOT	331
17.34.2 PRODUCT PORTFOLIO	331
17.34.3 RECENT DEVELOPMENTS	332
17.35 SCHOTT PHARMA	333
17.35.1 COMPANY SNAPSHOT	333
17.35.2 PRODUCT PORTFOLIO	333
17.35.3 RECENT DEVELOPMENTS	334
17.36 SHL MEDICAL AG	335
17.36.1 COMPANY SNAPSHOT	335
17.36.2 PRODUCT PORTFOLIO	335
17.36.3 RECENT DEVELOPMENT	336
17.37 SOCIETE INDUSTRIELLE DE SONCEBOZ SA	337
17.37.1 COMPANY SNAPSHOT	337
17.37.2 PRODUCT PORTFOLIO	337
17.37.3 RECENT DEVELOPMENT	337
17.38 TERUMO CORPORATION	338
17.38.1 COMPANY SNAPSHOT	338
17.38.2 REVENUE ANALYSIS	338
17.38.3 PRODUCT PORTFOLIO	339
17.38.4 RECENT DEVELOPMENT	339
17.39 TAKEDA PHARMACEUTICAL COMPANY LIMITED	341
17.39.1 COMPANY SNAPSHOT	341
17.39.2 REVENUE ANALYSIS	342
17.39.3 PRODUCT PORTFOLIO	342
17.39.4 RECENT DEVELOPMENT	342
17.40 TEVA PHARMACEUTICALS	343
17.40.1 COMPANY SNAPSHOT	343

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.40.2	REVENUE	343
17.40.3	PRODUCT PORTFOLIO	344
17.40.4	RECENT DEVELOPMENT	344
17.41	UCB PHARMA	345
17.41.1	COMPANY SNAPSHOT	345
17.41.2	REVENUE	345
17.41.3	PRODUCT PORTFOLIO	346
17.41.4	RECENT DEVELOPMENT	346
17.42	WEST PHARMACEUTICAL SERVICES	347
17.42.1	COMPANY SNAPSHOT	347
17.42.2	REVENUE ANALYSIS	347
17.42.3	PRODUCT PORTFOLIO	348
17.42.4	RECENT DEVELOPMENTS	349
18	QUESTIONNAIRE	350
19	RELATED REPORTS	353

Asia Pacific Self-injections Market

Market Report | 2024-09-01 | 353 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2025-05-12
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com